Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Prostate Cancer and Diet

Gold Nanoparticles Use in Prostate Cancer

Prostate Cancer Staging

Life after prostate cancer treatment

Hormonal therapy for prostate cancer

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

What is benign prostatic hyperplasia?

Prostate Cancer Treatment

What is Prostatectomy?

Brachytherapy for Prostate Cancer

See more featured articles »

Prostate Cancer Partin Tables

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Prostate Cancer and Exercise

Diagnosis of prostatitis

PSA False Positive and False Negative Results

What is medical castration?

The International Prostate Symptoms Score (IPSS)

Prostatitis symptoms

Single Nucleotide Polymorphisms and Prostate Cancer

Choosing the best treatment of prostate cancer - by stage

Prostate Cancer Diagnosis

What is Prostatitis?

What is the PCA3 Test?

Recent Genetic Breakthroughs in Prostate Cancer Research

Prostate cancer complications

The Prostate

Breakthroughs in Prostate Cancer Treatments

Radiation therapy for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

Treatment of prostatitis

Prostate Cancer Research

Prostate Cancer Cell Dormancy and Activation

Prostate cancer prevention

Differentiating between prostate cancer and prostate enlargement

Causes of benign prostatic hyperplasia

What is the Gleason Score?

Prostate Cancer Epidemiology

Prostate Cancer Screening

Palliative treatment and end of life care for prostate cancer

Cryosurgery for prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

What Should You Avoid Before a PSA Test?

Prostate Cancer and Genetics

Rectal Examination for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Survival rates of prostate cancer

Prostate cancer alternative and complementary therapies

Prostate Cancer Epidemiology Worldwide

Symptoms of Benign Prostatic Hyperplasia (BHP)

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Prostate Biopsy

Prostate Cancer Risk Factors

Types of PSA Test

Prostate Cancer Symptoms

What is the PSA Test?

Causes of prostatitis

PSA Test in Men Who Have Been Treated for Prostate Cancer

What is TURP?

Latest Prostate Cancer News and Research

USC-led study advances understanding of prostate cancer genetics in Black men

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and treatment for patients of African ancestry.

5 Nov 2025

PTGES3 emerges as key regulator of androgen receptor in prostate cancer

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer.

5 Nov 2025

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025

How walnuts combat inflammation and oxidative stress in the body

This review in Food Science & Nutrition synthesizes evidence showing that walnuts (Juglans regia L.) exert potent antioxidant, anti-inflammatory, apoptosis-regulatory, and immunomodulatory effects through bioactive compounds influencing mitochondrial, cytokine, and redox pathways.

3 Nov 2025

Study confirms PSA screening improves survival and safety

After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower prostate cancer mortality with PSA testing and an improved harm–benefit ratio over time. Risk-based screening could sustain mortality gains while reducing overdiagnosis and unnecessary treatment.

30 Oct 2025

Breakthrough combo therapy lowers death risk in recurrent prostate cancer

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

23 Oct 2025

Discovery offers a breakthrough approach to combat prostate tumor growth

Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.

22 Oct 2025

Study provides a new approach for the treatment of prostate tumors

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid hormone plays a key role in the development and progression of prostate cancer.

21 Oct 2025

New imaging technique boosts survival in prostate cancer patients

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph's Health Care London (Lawson), and University Health Network (UHN) has found a novel imaging solution, called prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scanning, can more effectively detect the recurrence of prostate cancer compared to standard imaging methods, and is associated with improved survival outcomes.

14 Oct 2025

Why brittle bones aren’t just a woman’s problem

Ronald Klein was biking around his neighborhood in North Wales, Pennsylvania, in 2006 and tried to jump a curb. "But I was going too slow — I didn't have enough momentum," he recalled.

14 Oct 2025

Blocking two enzymes weakens prostate tumors and boosts drug effectiveness

A major international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one of the most common cancers affecting men.

13 Oct 2025

Innovative screening tool launched to identify individuals at risk for hereditary cancers

Ochsner Health announces the launch of its Genetic Wellness Assessment, an innovative screening tool to help identify individuals at risk for hereditary cancers.

9 Oct 2025

Many men receive frequent prostate cancer tests without symptoms

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford in a study of over 10 million men across England published by The BMJ today.

8 Oct 2025

Housing support programs tied to improved cancer detection among seniors

A new study led by researchers from the Johns Hopkins Bloomberg School of Public Health found that older adults receiving federal housing assistance were on average diagnosed at earlier stages with three common cancers-colon, breast, and non-small cell lung-compared to peer cancer patients who were not receiving assistance.

8 Oct 2025

Scientists develop a high accuracy blood test to diagnose Chronic Fatigue Syndrome

Scientists at the University of East Anglia and Oxford Biodynamics have developed a high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS).

7 Oct 2025

Unlocking the mysteries of treatment-resistant prostate cancer

Advances in prostate cancer early detection and treatment have improved outcomes in men diagnosed with the disease.

7 Oct 2025

New drug combination could delay the progression of advanced prostate cancer

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

7 Oct 2025

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

New ASPIRE trial tests chemotherapy combination for advanced prostate cancer

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.

6 Oct 2025

Nuclear missile workers are contracting cancer. They blame the bases.

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.

3 Oct 2025